Marker Therapeutics Announces $16.1 Million Private Placement [Yahoo! Finance]
Marker Therapeutics, Inc. (MRKR)
Last marker therapeutics, inc. earnings: 11/12 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T cells HOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced it has entered into a securities purchase agreement for a private placement resulting in gross proceeds of $16.1 million, before deducting placement agent fees and other expenses. Proceeds from the financing will, among other uses, support the clinical advancement of the Company's Phase 1 APOLLO study investigating MT-601, a multi-antigen recognizing (MAR) T cell product (formerly known as multiTAA-specific T cells), in patients with lymphoma who have relapsed after anti-CD19 chimeric antigen receptor (CAR)-T cell therapy or where anti-CD1
Show less
Read more
Impact Snapshot
Event Time:
MRKR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRKR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRKR alerts
High impacting Marker Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRKR
News
- Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma [Yahoo! Finance]Yahoo! Finance
- Marker Therapeutics Announces $16.1 Million Private PlacementGlobeNewswire
- Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with LymphomaGlobeNewswire
- Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer [Yahoo! Finance]Yahoo! Finance
- Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic CancerGlobeNewswire
MRKR
Analyst Actions
- 10/21/24 - Ladenburg Thalmann
MRKR
Sec Filings
- 12/26/24 - Form 4
- 12/23/24 - Form 4
- 12/23/24 - Form 8-K
- MRKR's page on the SEC website